Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease

Thorax

Volumn 59, Issue 4, 2004, Pages 318-323

  Rubio, F ^a   Cooley, J ^a   Accurso, F J ^b   Remold O'Donnell, E ^a,c  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b Children's Hospital Colorado   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; DYFLOS; ELASTASE; MYELOBLASTIN; SERINE PROTEINASE; SURFACTANT PROTEIN A;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG LAVAGE; NEUTROPHIL; PRIORITY JOURNAL; SIMULATION;

ADOLESCENT; ADULT; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CATHEPSINS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; INFANT; NEUTROPHILS; PANCREATIC ELASTASE; PULMONARY ALVEOLAR PROTEINOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; SERINE ENDOPEPTIDASES;

EID: 1942437649     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2003.014902     Document Type: Article

References (36)

1. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002;109:707-12.
2. LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect 2001;3:161-6.
3. Sastry K, Ezekowitz RA. Collectins: pattern recognition molecules involved in first line host defense. Curr Opin Immunol 1993;5:59-66.
4. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-62.
5. Baughman RP, Sternberg RI, Hull W, et al. Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993;147:653-7.
6. LeVine AM, Lotze A, Stanley S, et al. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996;24:1062-7.
7. Griese M, Birrer P, Demirsoy A. Pulmonary surfactant in cystic fibrosis. Eur Respir J 1997;10:1983-8.
8. Postle AD, Mander A, Reid KB, et al. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol 1999;20:90-8.
9. Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989;143:2961-8.
10. Welsh M, Ramsey B, Accurso F, et al. Cystic fibrosis in the metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001.
11. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 1995;151:939-41.
12. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
13. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-13.
14. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-4.
15. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-54.
16. Cooley J, Takayama TK, Shapiro SD, et al. The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry 2001;40:15762-70.
17. Kuroki Y, Fukada Y, Takahashi H, et al. Monoclonal antibodies against human pulmonary surfactant apoproteins: specificity and application in immunoassay. Biochim Biophys Acta 1985;836:201-9.
18. Hiraike N, Sohma H, Kuroki Y, et al. Epitope mapping for monoclonal antibody against human surfactant protein A (SP-A) that alters receptor binding of SP-A and the SP-A-dependent regulation of phospholipid secretion by alveolar type II cells. Biochim Biophys Acta 1995;1257:214-22.
19. Chiba H, Sano H, Saitoh M, et al. Introduction of mannose binding protein-type phosphatidylinositol recognition into pulmonary surfactant protein A. Biochemistry 1999;38:7321-31.
20. Nakajima K, Powers JC, Ashe BM, et al. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem 1979;254:4027-32.
21. Powers JC, Harper JW. Inhibitors of serine proteinases. In: Salvesen BA, ed. Proteinase inhibitors. New York: Elsevier, 1986:55-152.
22. Schuster A, Fahy JV, Ueki I, et al. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors. Eur Respir J 1995;8:10-14.
23. Duranton J, Belorgey D, Carrere J, et al. Effect of DNase on the activity of neutrophil elastase, cathepsin G and proteinase 3 in the presence of DNA. FEBS Lett 2000;473:154-6.
24. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999;20:729-36.
25. Owen CA, Campbell MA, Boukedes SS, et al. Inducible binding of bioactive cathepsin G to trie cell surface of neutrophils. A novel mechanism for mediating extracellular catalytic activity of cathepsin G. J Immunol 1995;155:5803-10.
26. Doyle IR, Jones ME, Barr HA, et al. Composition of human pulmonary surfactant varies with exercise and level of fitness. Am J Respir Crit Care Med 1994;149:1619-27.
27. Korfhagen TR. Surfactant protein A (SP-A)-mediated bacterial clearance: SP-A and cystic fibrosis. Am J Respir Cell Mol Biol 2001;25:668-72.
28. Pison U, Tam EK, Caughey GH, et al. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta 1989;992:251-7.
29. Ryan SF, Ghassibi Y, Liau DF. Effects of activated polymorphonuclear leukocytes upon pulmonary surfactant in vitro. Am J Respir Cell Mol Biol 1991;4:33-41.
30. Schochett P, Mora R, Mark L, et al. Calcium-dependent degradation of surfactant protein A by activated neutrophils due to serine proteases. Exp Lung Res 1999;25:595-616.
31. von Bredow C, Birrer P, Griese M. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur Respir J 2001;17:716-22.
32. Griese M, von Bredow C, Birrer P. Reduced proteolysis of surfactant potein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001;22:165-71.
33. McCormack FX, King TE Jr, Bucher BL, et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;152:751-9.
34. Campbell EJ, Campbell MA, Boukedes SS, et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest 1999;104:337-44.
35. Mariencheck WI, Alcorn JF, Palmer SM, et al. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 2003;28:528-37.
36. Nooh TL, Murphy PC, Alink JJ, et al. Bronchoalveolar lavage fluid surfactant protein-A and surfactant protein-D are inversely related to inflammation in early cystic fibrosis. Am J Respir Crit Care Med 2003;168:685-91.